GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immunogen Inc (NAS:IMGN) » Definitions » Beneish M-Score

Immunogen (Immunogen) Beneish M-Score : 9.36 (As of May. 06, 2024)


View and export this data going back to 1989. Start your Free Trial

What is Immunogen Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score 9.36 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for Immunogen's Beneish M-Score or its related term are showing as below:

IMGN' s Beneish M-Score Range Over the Past 10 Years
Min: -5.31   Med: -1.5   Max: 34.33
Current: 9.36

During the past 13 years, the highest Beneish M-Score of Immunogen was 34.33. The lowest was -5.31. And the median was -1.50.


Immunogen Beneish M-Score Historical Data

The historical data trend for Immunogen's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immunogen Beneish M-Score Chart

Immunogen Annual Data
Trend Jun13 Jun14 Jun15 Jun16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.33 -1.47 -1.40 -2.72 -0.75

Immunogen Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.07 -0.75 0.78 4.10 9.36

Competitive Comparison of Immunogen's Beneish M-Score

For the Biotechnology subindustry, Immunogen's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Immunogen's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immunogen's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Immunogen's Beneish M-Score falls into.



Immunogen Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Immunogen for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 10.8788+0.528 * 1.0136+0.404 * 1.4137+0.892 * 3.0083+0.115 * 0.8923
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.5924+4.679 * 0.142785-0.327 * 0.8081
=9.36

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep23) TTM:Last Year (Sep22) TTM:
Total Receivables was $137.2 Mil.
Revenue was 113.425 + 83.153 + 49.869 + 41.167 = $287.6 Mil.
Gross Profit was 111.27 + 82.244 + 49.243 + 40.991 = $283.7 Mil.
Total Current Assets was $766.9 Mil.
Total Assets was $822.1 Mil.
Property, Plant and Equipment(Net PPE) was $12.8 Mil.
Depreciation, Depletion and Amortization(DDA) was $1.7 Mil.
Selling, General, & Admin. Expense(SGA) was $156.2 Mil.
Total Current Liabilities was $134.7 Mil.
Long-Term Debt & Capital Lease Obligation was $79.9 Mil.
Net Income was 30.748 + -4.248 + -41.014 + -59.008 = $-73.5 Mil.
Non Operating Income was -0.164 + -0.008 + 2.232 + 4.923 = $7.0 Mil.
Cash Flow from Operations was 2.77 + -66.741 + -73.719 + -60.199 = $-197.9 Mil.
Total Receivables was $4.2 Mil.
Revenue was 15.375 + 14.162 + 38.078 + 27.992 = $95.6 Mil.
Gross Profit was 15.375 + 14.162 + 38.078 + 27.992 = $95.6 Mil.
Total Current Assets was $330.4 Mil.
Total Assets was $358.8 Mil.
Property, Plant and Equipment(Net PPE) was $15.3 Mil.
Depreciation, Depletion and Amortization(DDA) was $1.8 Mil.
Selling, General, & Admin. Expense(SGA) was $87.6 Mil.
Total Current Liabilities was $103.6 Mil.
Long-Term Debt & Capital Lease Obligation was $12.2 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(137.158 / 287.614) / (4.191 / 95.607)
=0.476882 / 0.043836
=10.8788

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(95.607 / 95.607) / (283.748 / 287.614)
=1 / 0.986558
=1.0136

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (766.9 + 12.769) / 822.101) / (1 - (330.416 + 15.283) / 358.799)
=0.051614 / 0.036511
=1.4137

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=287.614 / 95.607
=3.0083

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(1.817 / (1.817 + 15.283)) / (1.726 / (1.726 + 12.769))
=0.106257 / 0.119076
=0.8923

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(156.181 / 287.614) / (87.642 / 95.607)
=0.543023 / 0.91669
=0.5924

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((79.872 + 134.66) / 822.101) / ((12.217 + 103.642) / 358.799)
=0.260956 / 0.322908
=0.8081

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-73.522 - 6.983 - -197.889) / 822.101
=0.142785

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Immunogen has a M-score of 9.36 signals that the company is likely to be a manipulator.


Immunogen Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Immunogen's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Immunogen (Immunogen) Business Description

Traded in Other Exchanges
Address
830 Winter Street, Waltham, MA, USA, 02451
Immunogen Inc is a clinical-stage biotechnology company from the United States. Its focus is antibody-drug conjugate, or ADC, technology, which uses an antibody that fixes on a target (its antigen) found on tumor cells to deliver a specific cancer-killing agent.
Executives
Theresa Wingrove officer: VP of Regulatory Affairs IMMUNOGEN, INC., 830 WINTER STREET, WALTHAM MA 02451
Renee Lentini officer: V.P.-Fin., Prin. Acctg. Off. 830 WINTER STREET, WALTHAM MA 02451
Stacy Ann Coen officer: Chief Business Officer 11 RUSH POND RD, LAKEVILLE MA 02347
Kristine Peterson director AMARIN CORPORATION, MYSTIC PACKER BLDG., 12 ROOSEVELT AVENUE, MYSTIC CT 06355
Lauren White officer: SVP, CFO and PFO C4 THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 200, WATERTOWN MA 02472
Mark J Enyedy director, officer: Chief Executive Officer C/O FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO CA 92121
Isabel Kalofonos officer: SVP & CHIEF COMMERCIAL OFFICER C/O IMMUNOGEN, INC., 830 WINTER STREET, WALTHAM MA 02451
Michael Vasconcelles officer: EVP R&D & MEDICAL AFFAIRS C/O UNUM THERAPEUTICS, 200 CAMBRIDGEPARK DR., STE. 3100, CAMBRIDGE MA 02140
Daniel Char officer: SVP & CHIEF LEGAL OFFICER C/O EVELO BIOSCIENCES, INC., 620 MEMORIAL DRIVE, SUITE 200, CAMBRIDGE MA 02139
Kristen Harrington-smith officer: SVP & Chief Commercial Officer C/O IMMUNOGEN, INC., 830 WINTER STREET, WALTHAM MA 02451
Tracey L Mccain director C/O BLUEPRINTS MEDICINES CORPORATION, 38 SIDNEY STREET, SUITE 200, CAMBRIDGE MA 02139
Helen M. Thackray director C/O GLYCOMIMETICS, INC., 401 PROFESSIONAL DRIVE, SUITE 250, GAITHERSBURG MD 20879
David G Foster officer: V.P.-Fin., Prin. Acctg. Off. C/O IMMUNOGEN, INC., 830 WINTER STREET, WALTHAM MA 02451
Susan Altschuller officer: SVP and CFO 45 TENNYSON ST., SOMERVILLE MA 02145
Craig Barrows officer: Vice-President,General Counsel C/O IMMUNOGEN, INC., 830 WINTER STREET, WALTHAM MA 02451